Home | News | Find a Doctor | Ask a Question | Free

Intercytex spreading itself too thin for a small company?

Intercytex H1 pretax loss widens but optimistic on product potential

LONDON (Thomson Financial) - Intercytex Group plc (LSE: ICX.L - news) reported a wider first-half pretax loss on higher research and administrative
expenses but said positive efficacy data on all its regenerative medicine products gives its ‘great optimism’ for their commercial potential.

The cell therapy company’s pretax loss for the six months to end-June came in at 6.04 mln stg compared with a loss of 4.04 mln stg in the year-earlier period.

The company said preliminary data from a Phase II trial of its Vavelta facial rejuvenation product shows encouraging efficacy data and a good safety profile, adding that it has started second Vavelta trial in acne scars.

Intercytex also said it has completed recruitment for Phase II trials in the UK in diabetic foot ulcers and expects to announce results in the first half of 2008.

Home | News | Find a Doctor | Ask a Question | Terms of Use & Privacy

This is an advertising site for paid advertisers to showcase successful hair restoration results only. It is not the mandate of this site to engage in the discussion of failed, unsuccessful procedures, lawsuits, litigations, refunds or complaint cases. Surgical hair restoration procedures carry risks. Please do thorough research, consult your own physician and investigate a doctor's background carefully before making a decision. By proceeding to use our site, you agree to abide by our Terms of Use & Privacy Policy at http://hairsite.com/terms-of-use/ where you can also find a list of HairSite's sponsoring physicians.